With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The 300 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

This year’s Fortune 500 marks the 68th running of the list.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-324-Quest Diagnostics

Millions of people turn to the laboratory company to conduct the important tests that track cholesterol levels, white blood cell count, and other crucial measurements that ensure healthy lives. Quest Diagnostics also helps pharmaceutical companies conduct the clinical trials that could lead to life-saving treatments.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

Quest Diagnostics Flies Coronavirus Tests and Samples Across the United States

The clinical diagnostics company’s services range from routine blood work to gene-based testing.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Strongest Dimension

Years on list

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Quest Diagnostics is a major diagnostic testing company, offering lab and direct-to-consumer tests that touch one in three U.S. adults every year and half the nation’s hospitals and doctors. Since its 1967 founding, the company has grown to have a presence in 130 countries. It works with hospitals, doctors, patients, insurers, government agencies, employers, and pharmaceutical companies, with more than 2,250 locations in the U.S. Quest operates under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Quest Diagnostics (DGX): Company Profile, Stock Price, News, Rankings

legacy

Quest Diagnostics

quest diagnostics

Welcome to the Quest Diagnostics 4th Quarter and Full Year 2024 Conference Call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and question and answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited. I'd now like to introduce Sean Bevec, Vice President of Investor Relations for Quest Diagnostics.

Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President and Sam Samad, our Chief Financial Officer. During this call, we may make forward looking statements and will discuss non GAAP measures. We provide a reconciliation of non GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected.

Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10 ks and subsequently filed quarterly reports on Form 10 Q and current reports on Form 8 ks. For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long term outlook projections, including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compound annual growth rates.

Thanks, Sean, and good morning, everyone. In the Q4, we delivered impressive revenue growth of nearly 15%, including approximately 5% organic growth, while also improving our profitability. For the full year, we drove revenue growth of close to 7%, including approximately 3% organic growth. In 2024, our team completed 8 acquisitions, including LifeLabs in Canada and 4 hospital outreach lab businesses in the U.

S. We also expanded our advanced diagnostics menu and drove sustained double digit growth in several clinical areas during the year. In addition, we attracted new business across the physician, hospital and consumer channels, while also forming new relationships with health plans to extend our geographic reach. Our investments in automation and AI delivered improvements in quality, customer experience and productivity during the quarter and throughout all of 2024, which helped us deliver on our annual 3% invigorate savings and productivity targets. We also meaningfully improved employee retention as we strengthened our position as employer of choice.

This morning, we provided guidance for 2025 that reflects our confidence in the core strength of our business, continuing robust utilization and the momentum from acquisitions we completed in 2024. These dynamics position us favorably to accelerate revenue and earnings growth in 2025. Now I'll recap our strategy and discuss highlights from the Q4. Then Sam will provide more detail on our financial results and talk about our financial guidance for 2025. Our strategy to drive growth is focused on delivering solutions that meet the evolving needs of our core customers, physicians, hospitals and consumers.

We enable growth across our customer channels through advanced diagnostics with an intense focus on faster growing clinical areas, including brain health, advanced cardiometabolic and molecular genomics and oncology. In addition, acquisitions are a key growth driver with an emphasis on accretive outreach purchases as well as other independent labs. Our strategy also includes driving operational improvements across the business with the strategic deployment of automation and AI to improve quality, service, efficiency and the workforce experience. Here are a few key updates on the progress we have made in these areas in the Q4 of 2024. Please note that my following comments are focused primarily on our U.

S. Operations. In Physician Lab Services, we delivered high single digit revenue growth, driven primarily by strong organic growth and contributions from acquisitions in the U. S. As a reminder, volumes from both hospital outreach and independent lab acquisitions originate in the physician offices.

Last month, we closed our acquisition of the outreach lab business of University Hospitals in Ohio and completed the transition of the business in January. We expect to moderate our pace of acquisitions in 2025 as we focus on driving growth from productivity from transactions completed last year. In addition to acquisitions, other growth drivers in the quarter included new customer wins as well as growth among large physician groups and community health centers. We also saw a step up in functional medicine testing as more people take an interest in prevention and wellness. In the Q4 and full year, we benefited from robust utilization compared to historical rates.

We also continue to see strong volume and revenue growth from Medicare Advantage Plans, which value our high quality, low cost testing for their narrow networks. We are well positioned to benefit from these dynamics as we expand access through our health plan partnerships with Elavance Health and Centerra Health Plans, both of which took effect on January 1. Today, we have access to more than 90% of the in network lives in the U. S. In hospital lab services, we grew revenues nearly 3 percent in the Q4, primarily due to solid continued demand for reference testing complemented by growth in professional lab services.

Hospitals continue to order a greater range of reference tests from our expanding advanced diagnostics menu rather than performing these tests in their own labs. By referring testing to us, hospitals are freed from the pressures that come from performing specialized tests in house, such as hiring skilled lab personnel and investing in expensive lab testing equipment. In Professional Lab Services, we completed 3 collaborations with health systems in Connecticut, New Jersey and Pennsylvania. We expect to see modest contribution from these relationships in early 2025. Looking at 2025, we expect hospitals to continue to struggle with high wage and supply inflation, constrained access to capital and keeping up to date with laboratory innovation.

At the same time, patients and payers want greater value from lab services. Hospitals increasingly recognize that Quest can improve access to innovative and cost efficient lab services through reference testing, lab management and outreach lab acquisitions. In consumer initiated testing, our consumer facing platform questhealth.com grew total revenues nearly 50% in the 4th quarter and approximately 40% for the full year to just over $60,000,000 Together with revenue from our channel partners, consumer initiated testing revenues grew to nearly $100,000,000 in 2024. During the year, we also greatly expanded our questhealth.com offering to include 135 different tests to provide a comprehensive platform for serving today's increasingly health minded consumers. In advanced diagnostics, we experienced double digit growth across several clinical areas in the Q4, including in brain health, advanced cardiometabolic, autoimmune and women's health.

We generated strong growth in brain health, largely due to impressive demand for our AD Detect blood tests for assessing Alzheimer's disease risk. We will continue to explore opportunities to extend our portfolio with new biomarkers that can help providers better assess Alzheimer's and other forms of dementia. We also generated strong growth in areas of advanced cardiometabolic and autoimmune testing and we expect these patterns to continue in 2025. Our growth in women's health was driven largely by prenatal and hereditary genetic testing. We were also pleased to see strong adoption of our self collection option for testing of genital tract infections during the quarter.

In Molecular Genomics and Oncology, we spent much of last year developing and validating our Haystack MRD blood test to aid in the early detection of minimal residual disease from solid tumor cancers. We also engaged with approximately 75 leading academic health systems and community oncology centers in our Haystack MRD Early Experience program and are pleased with the favorable feedback we received. We are now transitioning these organizations to a commercial program and are focused on expanding utilization among medical oncologists. Turning to operational excellence, Our Invigorate program delivered our targeted 3% annual cost savings and productivity improvements. Here are some examples of how we're improving operations.

We pilot many of our automation and AI solutions at our laboratory in Clifton, New Jersey. During the Q4, we developed and implemented a proprietary system in Clifton that automates labeling and test tube preparation for tuberculosis testing, eliminating manual intervention and improving quality. In addition, we began testing an automated assessing solution that speeds requisition processing. Also in Clifton, we deployed a 3rd party AI solution that enhances parasitology screening by flagging likely positive specimens requiring closer human examination. We plan to roll out these solutions to our other labs later in 2025.

Improving workforce engagement remains a major priority and I'm pleased that our retention rates significantly improved across multiple job categories in 2024. Now before I turn it over to Sam, I want to thank our more than 55,000 Quest and LifeLabs colleagues for delivering on our business imperatives last year. This amazing group of people is the engine behind our growth and the reason we entered 2025 strong, energized and ready to deliver on our purpose, working together to create a healthier world, one life at a time. And now Sam will provide more details on our performance and 2025 guidance. Sam?

Thanks, Jim. In the Q4, consolidated revenues were $2,620,000,000 up 14.5% versus the prior year. Consolidated organic revenues grew by 4.8%. Revenues for Diagnostic Information Services were up 15.1% compared to the prior year, reflecting the contributions from recent acquisitions including Life Labs as well as growth in our key physician and hospital channels. Total volume measured by the number of requisitions increased 13.9% versus the Q4 of 2023 with organic volume growing by 0.6%.

During the quarter, weather negatively impacted volume by approximately 50 basis points. Total revenue per requisition was up 0.2% versus the prior year, driven primarily by an increase in the number of tests per req and favorable test mix, mostly offset by the impact of the LifeLabs acquisition, which carries a lower revenue per requisition. On an organic basis, revenue per req was up 3.3% in the quarter versus last year. Unit price reimbursement was relatively flat, consistent with our expectations. Reported operating income in the 4th quarter was $361,000,000 or 13.8 percent of revenues compared to $267,000,000 or 11.7 percent of revenues last year.

On an adjusted basis, operating income was $409,000,000 or 15.6 percent of revenues, compared to $338,000,000 or 14.8 percent of revenues last year. The increase in adjusted operating income was due to strong organic revenue growth and the impact of recent acquisitions, partially offset by the impact of weather, wage increases and higher performance based compensation. We estimate the impact of weather on operating margin to be approximately 30 basis points. Reported EPS was $1.95 in the quarter compared to $1.70 a year ago. Adjusted EPS was $2.23 versus $2.15 the prior year.

Adjusted EPS in the 4th quarter was impacted by higher interest expense and a higher tax rate versus the prior year. We estimate the EPS impact of weather to be approximately $0.06 in the quarter. Cash from operations was $1,330,000,000 in the full year 2024 versus $1,270,000,000 in the prior year. Turning now to our full year 2025 guidance. Revenues are expected to be between $10,700,000,000 $10,850,000,000 Reported EPS expected to be in a range of $8.34 to $8.59 and adjusted EPS to be in a range of $9.55 to $9.80 Cash from operations is expected to be approximately $1,450,000,000 and capital expenditures are expected to be approximately $500,000,000 We have posted a presentation on the Investor Relations page of our website that includes an adjusted EPS bridge, which shows some of the key elements to bridge from our 2024 adjusted EPS to the 2025 adjusted EPS guidance we shared today.

Our 2025 guidance reflects the following considerations. Our revenue guidance assumes approximately 3% organic revenue growth with the remainder coming from the acquisitions closed in 2024. It does not assume any contribution from prospective M and A that could be completed in 2025. As you know, we absorbed the headwind last year related to the CrowdStrike IT outage, which we do not assume repeats in 2025. We expect to begin generating revenue from the launch of our Haystack MRD test in 2025 and continue to anticipate that Haystack Oncology will be slightly less dilutive versus the prior year.

We are making investments in 2025 to modernize our IT infrastructure as well as to comply with FDA regulations of laboratory developed tests that are scheduled to begin later this year. Operating margin is expected to expand versus the prior year. We anticipate net interest expense to be approximately $275,000,000 Adjusted tax rate is expected to be approximately 25 percent and our average share count for the full year is expected to be approximately 114,000,000 diluted shares outstanding. With that, I will now turn it back to Jim.

Thanks, Sam. To summarize, we delivered strong consolidated and organic revenue growth in the Q4 and the full year. We expanded our presence in important new geographies, including Canada through 8 acquisitions and new health plan relationships. Our innovations in advanced diagnostics drove meaningful growth and Haystack MRD strengthens our position in molecular genomics and oncology. Given these business strengths and robust utilization, we expect to accelerate revenue and earnings growth this year.

And now we'd be happy to take your questions. Operator?

Thank you. We will now open it up to questions. Our first question will come from Kevin Caliendo with UBS. Your line is open, sir.

Thank you. Thanks for getting me in so early. Appreciate it. Just a question on guidance and some of the assumptions that are in there. I appreciate the earnings bridge.

I guess what I'm trying to understand a little bit is there's $20,000,000 of additional investment spend for LDT and IT. What are there any other one timers in there? And specifically, is do you expect core margins, not sort of comping out some of the other things that have happened, but you said margins expect to expand. Does the guidance assume that just that core margins will expand ex all of the sort of one timers that we had from last year or the accretion from deals and things happening? I want to understand that and weather, if there's any weather built in from 1Q, whether it's the fires or the frozen tundra that we had to deal with.

Yes. Thanks, Kevin. This is Sam and good morning. Let me just give some comments on guidance to address your question. First of all, the one timers that you're asking about, they're all laid out in the bridge that we've included.

There are no additional one timers that you should be adding in or taking out. The key things I think from a positive standpoint that we talked about in addition to the organic revenue growth and the M and A contribution is a benefit related to CrowdStrike, which obviously we don't expect to repeat in 2025. We've got some benefits in terms of the Haystack reduced dilution, so some benefit year over year. But then from an offset in terms of headwinds, we talked about the investments and we can share some more comments on that. And it really relates to the FDA LDT compliance investments to get us in compliance with that and to build up our regulatory capabilities.

In addition to some investments in terms of modernizing our systems and our IT systems and the lab information systems and we can talk some more about that. Interest expense, we've talked about the fact that we had to fund the acquisitions that we took on, especially Life Labs, that represents a $0.50 headwind. And then there are some other headwinds that are laid out there. In terms of weather, we have not built any specific explicit assumption related to worse weather as a result of what we're seeing. But obviously, we're monitoring Q1 and January closely because there have been some higher than expected weather disruptions, specifically the wildfires in California, specifically the freeze in the south and some of the snow that we've seen, also some lower temperatures in the northeast and snow as well.

So there are some of these. In terms of operating margin, we are expecting operating margin expansion in terms of what we report. There's you don't have to normalize or make adjustments to get to expanded operating margins. We are expecting that our operating margin percentage, which finished at 15.6% in 2024 will expand in 2026 or in 2025, I should say.

Yes. Hey, Kevin, let me just provide a little more color on the investment. So as Sam said, there's 2 parts to it. 1 is, in preparation for the FDA requirements. Now the first set of requirements go into effect on May 6 this year.

And notably, we have to stand up a complaint handling unit and enable ourselves to report any, what we call medical device reporting to the FDA. So that does require some investment. It requires some additional resources to do that. So in part, that is what some of those investments are used for. The second and more substantial piece is, look, as you all know, this is a digital enterprise that we operate today from order intake to our logistics systems, to how we operate the labs, to how we provide results through our MyQuest application and our entire billing system.

We think about that as our entire order to cash spectrum of systems. And while we have been making investments from time to time, we need to make some more substantial investments this year and next year. And the benefits from those investments are certainly going to help us improve operations and improve the entire customer experience. So we're modernizing this IT infrastructure. We're going to migrate some of our current systems into cloud based systems.

And over time that's going to dramatically reduce the complexity. It's going to create more efficiencies between our labs and it's really, really going to improve the overall customer experience. Ultimately, it's going to lower our IT costs and there's going to be a good ROI on these investments. We're going to lay this out more at our Investor Day on March 19, but that's really what that $0.20 is being used for.

The next question will come from Patrick Donnelly of Citi. Your line is open.

Hey, guys. Thank you for taking the questions. Sam, maybe one for you to start. Just helpful to hear you talk about the margin expansion this year overall. Can you just talk about the cadence?

Anything to call out as the year progresses? I know LifeLab is starting lower margin. It's heading to corporate average at some point. So maybe just talk through that would be helpful. And then Jim, just quickly on utilization, obviously been elevated here.

What have you seen as you exited 4Q into this year and just the assumptions on utilization as we work our way through 2025? Thank you guys.

Yes. Thanks, Patrick. So, on margin, so yes, again, let me reiterate, we are expecting margin expansion this year versus 2024. I think the components that you see in the bridge that we laid out in the guidance, organic revenue growth approximately 3% at the midpoint, that's basically assumed that a contribution margin that comes in at roughly about 40%. Then you have the acquired revenue growth, which is roughly, let's call it $0.70 at the midpoint, is basically a combination of LifeLabs, which is the more significant piece because of the fact that we have 3 quarters in 2025 that we didn't have in 2024 or at least the better part of 3 quarters.

And that will come in at a margin rate, which is in the lower double digits or in the low double digits, I should say, so below our corporate average. I think you mentioned it and you're right. LifeLabs will start at a margin rate, which is low double digits, will ramp up over 2 to 3 years to get to our corporate average. But this year, it will be lower and it's a bit of a drag on the margin rate. But in terms of the other acquisitions, they come in at somewhere in the 35% to 40% contribution margin.

Margin. So all in that acquired revenue growth is probably coming in at the high teens in terms of contribution margin. Now you asked about the cadence and I won't talk about margin rate, although it is a bit of a proxy in terms of how EPS will come in. But I think the best way to talk about cycling is really go back to our pre COVID averages in terms of what the cycling was by quarter. And I'll just mention these just as a comparative point.

It doesn't necessarily mean that our cycling is going to be exactly that in 2025, but it's a good proxy and it's a good proxy for how margin rate also will be across the quarters. But in terms of contribution from EPS, I would say roughly 22.5% is what we used to see pre COVID in the Q1, 26.5% in the second, 26% in the third and approximately 25% in the 4th. Now again, I'm not telling you this is what our cycling is in 2025, but it's directional and it's a good proxy for what you would expect close to cycling to be in 2025. So that's what we used to see pre COVID.

Yes. And then your question on utilization, look, we're pleased with the utilization coming out of the Q4. We look at it in many ways and across many segments. In terms of overall rec volume, we did have a slight weather impact in the quarter because of the hurricane early in Q4, so that cost us probably 50 basis points. And then we've been getting out of certain capitated business arrangements in California that were impacting just business we weren't making money on.

So we walked away from that and that cost us a little volume. But when we look at the volume in our core physician and hospital segment, the rec volume from those segments was very, very strong in the quarter. Now as Sam also mentioned, our rep per rec organically ex ex LifeLabs was up 3.3% in the quarter. And as you know, there's a lot of things that go into that rep per rec calculation. The first thing we look at is price per test that was relatively flat in the quarter.

But the second and biggest driver of that rep per rec increase is test per rec. And that was, probably 2 thirds of the increase in the overall organic rep per rec in the quarter. And so that's utilization as well. And what's driving it is some of the new tests that we've rolled out, the brain health, AB-four thousand two hundred and forty in the tau markers, our advanced cardiometabolic testing, we're seeing big increases in things like Lp and APO B. Our autoimmune testing has been really propelling some of the test per rec growth.

And then finally, I'd mention, we're seeing a nice uptick in volume from what we call functional health types of physicians. And as you probably know, they look at a lot of things and a lot of hormone testing and things like that. So the trends on test per rec, the trends on volume in our core physician and hospital segment remain very, very strong.

The next question comes from Michael Cherny of Leerink Partners. Your line is open, sir.

Good morning. Congratulations on a great quarter. Maybe if I can just pull a little bit that thread there on rev per rec. It's obviously a really strong year over the course of 2024. As you think about that dynamic heading into 2025 beyond, how much of the continued technological advancements are the drivers of this versus payer arrangements and marketing?

And how should we think about this in terms of a long term trajectory?

Okay. So again, let's fast forward into 2025. We'll start with price, price per test. At this point in the year, it could probably swing between plus or minus 30 basis points, okay? There's still lots of contracts to negotiate as we go through the year.

And the one segment that has been experiencing some price pressure is the hospital segment, in particular reference testing. I think we've indicated on the past calls during the entire COVID period from 2020 through 2023, hospitals really didn't go out to RFP for reference testing providers, right? They were so busy with other things. So we're seeing an uptick in RFPs and there's still price pressure in that segment. So on par though, look, we think it's again within a range of plus or minus 25 to 30 basis points.

The test per rack, we expect it to continue. We're still at the very early stages. So when I talk about incredible test growth on things like APOB and LP and the brain health portfolio, the overall volume of these tests is still relatively low. So we still think there's significant growth in these segments left. Autoimmune disorders is another one.

We're just seeing skyrocketing autoimmune disorders across the country. So we expect those trends to continue. The last thing that goes into it is payer mix. And I didn't mention, but in the Q4 and we saw it all last year, our mix of Medicare, Medicare Advantage, that segment of our business has been growing faster than the rest of the business. And so that is actually good business mix because they're generally heavier recs, they're more frequent recs.

And as you know, many Medicare beneficiaries have comorbidities that just lead to more testing. So all of that is pretty favorable.

Maybe I can have just a couple of comments, Mike, from a financial standpoint. In terms of if you look at the rep per rec, in Q4, it was up 3.3% organically. If you break that down between the components that Jim talked about, 2 thirds of that is really a benefit from test per rec, which has been increasing continuously over the last number of quarters. And then the other third benefit is really a combination of payer mix and test mix. Test mix being some of the innovations that we have, payer mix is just driven off of reimbursement and which payers we're getting the contribution from the different payers.

As we look towards 2025 or this year, test per rec will continue to improve, although our expectation is that it will slow in terms of the improvement. So that improvement, we don't expect it to be at the same pace that we've seen. I mean, we have been increasing quite substantially over a number of quarters. And I wouldn't say we've peaked, but definitely that rate of improvement is not going to be at the same rate. So that's the only other comment that I would provide with regards to rev rec expectation in 2025.

The next question comes from Elizabeth Anderson of Evercore ISI. Please go ahead.

Hi, thanks for the question. This is Joanna for Elizabeth. Maybe go back to that $0.20 IT investment for 0.25 dollars I think you guys said that's most related to the LDT regulation. Is that expected to be a one time investment? Or should we kind of expect to repeat in $0.26 and beyond?

Yes. First we said on the $0.20 the majority of it will be on modernizing our IT infrastructure, but there is a portion in there that is for FDA readiness. Now it's difficult to tell what the future will be for that. As you know, there's a lawsuit in front of the courts right now that ACLA and other trade associations brought. And there'll be oral hearings on that lawsuit on February 19.

And we expect the case to likely be settled by the end of the Q1 or early Q2. So depending on the outcome of that, if the outcome supports the FDA position, then yes, there'll be some continued investments. If the outcome favors our trade association, then those investments could certainly moderate. Now remember, outside of, what we're doing on the core clinical business to get ready, we do have segments in Quest Diagnostics that already operate under 21 CFR Part 820. These are segments that serve our pharmaceutical industry customers.

And so, there will continue to be some investments to improve those systems in readiness. But look, a lot of the future investments related to the FDA will depend on the court case.

And then the other part of that $0.20 that you referenced is the IT investments that we're going to make that Jim talked about earlier. Those investments will continue. We have investments to modernize our systems. So we don't expect that to be just this year. However, we talked on the Q3 call about our long term guide in terms of expecting high single digit EPS over the long term and that we still we reaffirm.

So those investments will continue, but they're part of our long term guide expectation.

The next question comes from Luke Sergott of Barclays. Your line is open.

This is Salem on for Luke Sergott. Thanks for the questions. Just to start off, could you guys provide a little more detail on what you expect the revenue contribution will be for the Outreach Lab Services business acquisition you guys had with University Hospitals? And then assuming you'll get some benefit from the value based contracts you have in place with payers, first, what's like the typical rate you get on top of your average reimbursement at the onset of these contracts? And how does that trend down in the next couple of years?

And can we expect that kind of typical rate for this transaction?

Maybe I'll start with the university hospital one and want to talk about value based compensation or incentives in general. But in terms of University Hospital, we made this acquisition. We closed it at the end of the year, so right at the end of 2024. It's an acquisition of roughly 180,000,000 dollars We don't usually provide revenue per each of these outreach acquisitions. So we're not going to provide exactly what the revenue is, but I'll give you a couple of points here to consider.

Usually there's a certain valuation that we pay for those acquisitions, which is somewhere around 3.5x of revenues. That doesn't mean that's what University Hospital is, but there's a certain valuation we pay for these outreach acquisitions. And this is a ballpark kind of number on average. And then the other piece that you need to consider is that this contribution from University Hospital is going to be in that acquired revenue growth bar that you see in the bridge that we have included on our website. And so it's part of that $0.65 to $0.75 contribution in terms of EPS from acquisitions.

Now as I said before, LifeLabs is a healthy portion of that. There's other carryover from outreach acquisitions that we made in 2024 beyond just university, but that is included in that piece. Jim, did you want to give any comments on value based incentives?

Yes. Yes. From time to time and we didn't really see any in the Q4, but from time to time, we get value based incentive payments that are tied to moving, reqs from expensive health systems into Quest Diagnostics. That generally helps the payer obviously and as importantly it helps the employer and it helps the patient. And so some of those incentives come at a 6 month period, some come after a 12 month period look back.

So they're hard to predict. And again, we call them out generally in our quarterly results when they do occur. Now the other way we do collect some of these incentives is when we make these outreach acquisitions and as you know, some of these health systems are getting 2x to 3x, the rates that we're getting. Over time, our rates, don't just migrate exactly to Quest Diagnostic rates. They'll come down over a period of 2 to 3 years.

And so there's what I call incremental pricing as we move it from a health system payer rate to a Quest Diagnostics payer rate. Sometimes those come as bonus payments and sometimes it's just part of the overall pricing.

The next question comes from Pito Chickering of Deutsche Bank. Your line is open, sir.

Hey, good morning guys. Thanks for taking my question. Looking at the competitive environment, you expanded access in several states in 2025 with 2 payers then lost one state. How do you see the landscape shaping up in 2025? And do you see more RFPs coming up this year that could result in more turnover sort of next year?

It's just been a couple of years seeing sort of this much volatility with states turnover?

Yes. So, first of all, net net on all of the payer changes that came about in 2024, we're better off. So when we look at the lives that we picked up through Elavance in Colorado, Nevada, Virginia and we were not in network with some of the plants in Georgia, When we look at the lives that we pick up from Centerra and then we subtract the lives we lost in Alabama, we're better off by well more than 1,000,000 lives. So our access in total has significantly improved as we enter 2025. In terms of agreements that we will negotiate here in 2025, Look, as you know, the typical health plan contract is somewhere between 3 5 years.

So every year, we renew somewhere between 25% 30% of health plan arrangements. And this year will be in that typical range. So more to come on that, but every year we're renewing agreements in that magnitude and we're to do it again this year.

The next question will come from David Westenberg of Piper Sandler. Your line is open.

Hi. Thank you for taking the question. So just on the acquisition and integration, I believe you completed, my count is 8 acquisitions in 2024, including big ones like LifeLab, had a lot of inorganic growth. How do you expect those acquisitions to enhance the revenue stream? And how should we think about as they lap the organic revenue growth?

Would that actually accelerate? And just thinking about puts and takes on integration speed, what exactly do you have to do this year, given the amount of acquisitions you did in the last year? And what would make you go back to a little bit more aggressive acquisitions, just given the fact that there is a lot out there available to you? Sorry, that was long.

Yes, sure. So, as Sam indicated in his comments, the 2025 revenue growth that is coming from acquisitions, carryover acquisitions is about 6%. And as you know, we only carry that growth through the date through the 12 month anniversary, okay? So we closed LifeLabs in September of last year. It had 5 months of impact, 4 months of impact last year.

And so we carry that through the 1st 7, 8 months of this year. So in total, it's about 6 percentage points of our growth in 2025. And more than 2 thirds of that is life laps, okay. So we feel good about that. Now, yes, the team is hard at work at integrating these acquisitions and yet the funnel of opportunities remains strong.

So we'll continue to assess the opportunities. We're not backing away from any. If it fits our criteria of we have great payer access in that market, if our share is very small in that market, then it becomes an attractive opportunity for us to look at. So, while we have a lot of work to do to integrate what we've got on our plate, we're not going to be shy about picking things up and going after things that improve our market access.

Maybe I can add just a couple of quick comments, Dave. You talked about sort of difficulty of integration and complexity of integration. And yes, there were a lot of acquisitions in 2024. Now remember Life Labs is more of a standalone entity that's in Canada, it's an established company. They have labs that are established.

There's a lot of things that they can learn from us, but we can learn from them as well. So I would say the integration is lighter there because they are already operating and we're not looking to close labs or move them to our systems at this point. So that's an easier integration. And then you asked about sort of the cadence of M and A, what would it take to do more. Just keep in mind, I mean, we're not it's not that we're not doing any more M and A in 2025.

We have not included in our guide any new M and A that has not been announced, but we do have in our capital plan, we have allocated certain capital for potential what we call tuck in M and A. It's mostly focused on the hospital outreach lab acquisitions. So we will do more M and A because these are very attractive opportunities that scale very quickly and get to a healthy contribution margin. So I just want to make sure that people don't expect that we're not going to do any more M and A.

The next question comes from Andrew Brackmann of William Blair. Please go ahead with your question.

Hi, guys. Good morning. Thanks for taking the questions. I wanted to ask on Haystack. First, can you maybe just sort of set a little bit more light on any volume or reimbursement expectations for that asset in 2025?

But I guess also bigger picture here and way more important than 2025. As you're moving these customers to those commercial programs, how should we be thinking about any additional pull through or halo effect that having this asset now in the commercial phase should allow on the oncology side of the business? Thanks.

Quest Diagnostics (DGX) Q4 2024 Earnings Call Transcript

Company Participants